Table 1.

Pretreatment Patient Characteristics

	CRT + 5-FU (n=230)		CRT + Gemcitabine (n=221)
Age
Median	62		61
Min-Max	36-81		33-84
	n	%	n	%	Chi-square p-value
Gender
Male	139	60	117	53	0.11
Female	91	40	104	47
Primary Tumor Location					0.40
Head	201	87	187	85
Non-Head	29	13	34	15
Tumor Grade					0.26
Well differentiated	40	17	28	13
Moderately differentiated	124	54	117	53
Poorly/Undifferentiated	54	23	67	30
Unknown	12	5	9	4
Largest tumor dimension of primary					0.33
<3 cm	100	43	86	39
≥ 3cm	130	57	135	61
N-stage (surgical)					0.37
N0	82	36	70	32
N1	148	64	151	68
Surgical Margins					0.49
Negative	102	44	86	39
Positive	75	33	77	35
Unknown*	53	23	58	26
T-stage (surgical)					0.013
T1/T2	68	30	43	19
T3/T4	162	70	178	81
CA19-9 Category†					0.76
< 180	113	88	107	86
≥ 180	16	12	17	14

^*Not mentioned/commented on pathology report

^†Pretreatment CA19-9 values for Lewis Antigen positive patients (negative patients do not express CA19-9)